You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -5,491.7% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | 0.9 | 0.0 |
| PEG | -0.2 | -999,999.0 |
| Price / Revenue | 83.9 | 0.0 |
| Price / Book value | 2.3 |
| Latest | Forecast | |
|---|---|---|
| Revenue | -7.7% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | -5.2% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | 0.15 | -7.00 | -4.75p | -35.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-12-31 | 0.08 | -7.96 | -5.19p | -2.3 | 0.0 | n/a | n/a | 0.0% |
| 2019-12-31 | 0.08 | -6.74 | -3.99p | -4.0 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 0.13 | -7.25 | 3.43p | 3.9 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 0.12 | -8.94 | 3.25p | 2.0 | -0.4 | -5% | n/a | 0.0% |
| ImmuPharma's US partner receives FDA response on Lupuzor Sharecast News | 14 Sep |
|---|---|
| ImmuPharma making final preparations for Lupuzor phase 3 trial Sharecast News | 04 May |
| ImmuPharma surges on success in latest trial of lupus treatment Sharecast News | 13 Apr |
| Written Response received from the FDA | 14-Sep-22 10:05 |
|---|---|
| Exercise of Options | 07-Sep-22 08:27 |
| FDA response for Type C Meeting - update | 31-Aug-22 07:01 |
| Exercise of Options | 30-Aug-22 11:32 |
| Exercise of Options | 24-Aug-22 08:13 |